September 13, 2011 -- Marcea Bland Lloyd, one of Amylin’s executive officers, was promoted to the role of Senior Vice President, Chief Administrative Officer (CAO) and General Counsel. In her expanded role, Ms. Lloyd will assume oversight, planning and implementation of policies related to staffing and human resources at Amylin, while maintaining responsibility for the Company’s legal, government and corporate affairs functions. Ms. Lloyd previously served as Senior Vice President, Government & Corporate Affairs and General Counsel since February 2007.
In the CAO function, Ms. Lloyd will leverage her experience as a top-level manager with significant career accomplishments and strong leadership qualities to further enhance the efficiency and competitive position of Amylin. She will focus on the development and progress of Amylin’s employee base at the Company’s corporate headquarters in San Diego and its manufacturing facility in West Chester, Ohio. She also will head up the recruitment of strategic talent to help expand the Company’s capabilities across several key business functions.
Harry Leonhardt, also an executive officer, was promoted to the role of Senior Vice President, Legal and Compliance, Deputy General Counsel and Corporate Secretary. In his expanded role, Mr. Leonhardt will assume oversight of Amylin’s compliance department and will lead the Company’s global compliance programs for its marketed diabetes therapies and clinical stage compounds. In addition, he will remain responsible for Amylin’s legal, corporate, licensing and intellectual property affairs and will continue to serve as counsel to the Company’s Board of Directors. Mr. Leonhardt served as Amylin’s Vice President, Legal since 2008 and assumed the Corporate Secretary function in 2010. Previously, he served as Amylin’s Vice President, Chief Intellectual Property Counsel.
Mr. Leonhardt is an accomplished legal professional with strong leadership skills, drawing on more than 28 years of corporate, intellectual property, litigation, executive management and mergers and acquisitions experience, focused in the biotechnology and pharmaceutical industries.
Ms. Lloyd and Mr. Leonhardt assume their expanded roles at an exciting time for the Company. Amylin has two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Additionally, along with its partner Eli Lilly and Company, Amylin recently received marketing authorization in the European Union (EU) for BYDUREON® (exenatide 2 mg powder and solvent for prolonged release suspension for injection). BYDUREON, currently under review with the U.S. Food and Drug Administration (FDA), is the first ever once-weekly therapy to treat diabetes and has the potential to transform diabetes care.
About Marcea Bland Lloyd
Senior Vice President, Chief Administrative Officer and General Counsel
Ms. Lloyd currently serves as Senior Vice President, Chief Administrative Officer and General Counsel of Amylin Pharmaceuticals, Inc. She previously served as Senior Vice President, Government & Corporate Affairs and General Counsel since February 2007. Prior to joining Amylin, Ms. Lloyd served as Group Senior Vice President, Chief Administrative Officer, General Counsel and Secretary of VHA Inc. from November 2004 to February 2007. Previously, she served as VHA’s General Counsel and Secretary from May 1999 to November 2004. From 1993 to April 1999, Ms. Lloyd was Vice President and Assistant General Counsel of Medtronic, Inc. and served as Medtronic’s Assistant General Counsel from 1991 to 1993. From 1978 to 1991, Ms. Lloyd held various legal positions with Medtronic. Prior to joining Medtronic, Ms. Lloyd served as counsel to Pillsbury Company and Montgomery Ward & Co. and taught Business Law at the University of Minnesota Business School.
Ms. Lloyd is immediate past Chairperson of the Executive Leadership Foundation, a member of the board of directors for California Healthcare Institute (CHI) and is an associate of the Women Business Leaders of the United States Health Care Industry Foundation. She received a B.S./B.A. from Knox College and a J.D. from Northwestern University.
About Harry J. Leonhardt
Senior Vice President, Legal and Compliance, Deputy General Counsel and Corporate Secretary
Mr. Leonhardt currently serves as Senior Vice President, Legal and Compliance, Deputy General Counsel and Corporate Secretary of Amylin Pharmaceuticals, Inc. He served as Vice President, Legal since October 2008 and as Corporate Secretary since June 2010. He previously served as Vice President, Chief Intellectual Property Counsel. Mr. Leonhardt has over 28 years of corporate, intellectual property, litigation, executive management and mergers and acquisitions experience. Prior to joining Amylin, Mr. Leonhardt served as Senior Vice President, General Counsel and Corporate Secretary of Senomyx, Inc. from September 2003 to September 2007. From February 2001 to September 2003 Mr. Leonhardt was Executive Vice President, General Counsel and Corporate Secretary of Genoptix, Inc. and from July 1996 to November 2000 he served as Vice President and then Senior Vice President, General Counsel and Corporate Secretary of Nanogen, Inc. From January 1990 through June 1996 Mr. Leonhardt served in various legal and management capacities at Allergan, Inc. Prior to that Mr. Leonhardt was an attorney with Lyon & Lyon LLP in Los Angeles where he represented a number of prominent pharmaceutical, biotechnology and consumer products companies. Mr. Leonhardt is a member of the California State Bar and is admitted to practice in the U.S. District Court, Central and Southern Districts, the California Supreme Court, the Court of Appeals for the Ninth Circuit and the Court of Appeals for the Federal Circuit. He is a member of the American Bar Association, Licensing Executives Society, San Diego Bar Association, San Diego Intellectual Property Law Association and BIOCOM, a regional life science association. He also serves as a Special Master through the California State Bar. Mr. Leonhardt received his B.S. in Pharmacy from the University of the Sciences and his J.D. from the University of Southern California School of Law.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development, and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin’s research and development activities leverage the Company’s expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California and has a commercial manufacturing facility in Ohio. Further information on Amylin Pharmaceuticals is available at www.amylin.com
